- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Failure
The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.
Northwestern Medicine Develops 30-Year Heart Failure Risk Prediction Model
January 06, 2022
New research published in Circulation Research suggests investigators at Northwestern Medicine have developed and validated sex- and race-specific equations for calculating lifetime risk of incident heart failure.
Hypertensive Disorders of Pregnancy Linked to Increased Heart Failure Risk
December 14, 2021
An analysis of data from the Women's Health Initiative suggests a history of hypertensive disorders of pregnancy was associated with an almost doubling in odds of developing heart failure later in life.
Meta-Analysis Details Effects of SGLT2 Inhibitors in HFpEF
December 01, 2021
A systematic review and meta-analysis of phase 3 data on SGLT2 inhibitors in HFpEF suggest the class was associated with a 22% reduction in CV death and hospitalization but found no significant effect on CV death or all-cause mortality as individual end points.
Optimal Prescription of SGLT2 Inhibitors in Hospitalized HFrEF Patients Could Provide Substantial Benefit
November 15, 2021
The most recent analysis from TRANSLATE-HF suggests optimal prescription of dapagliflozin, based on the FDA label, could reduce the risk of mortality and readmission among patients hospitalized for HFrEF.
Deepak Bhatt, MD, MPH: Sotagliflozin Provides Consistent Benefit Across Spectrum of Kidney Function
November 14, 2021
Deepak Bhatt, MD, MPH, discusses the results of a pooled analysis of the SOLOIST and SCORED trials assessing effects of sotagliflozin based on baseline eGFR among patients included in the trials.
Statins Lower Risk of MACE in Patients with Heart Failure
November 14, 2021
Viet Le, PA-C, discusses the results of an observational analysis examining the risk of MACE associated with statin use in patients with heart failure.
Final Thoughts on Heart Failure
November 04, 2021
The panel provides their final thoughts on the management of heart failure.
Challenges With Initiating New Therapies for Heart Failure
November 04, 2021
Gregg Fonarow, explains the challenges clinicians face when initiating new therapies for patients with heart failure.
Medical Adherence in Patients With HFrEF and HFpEF
November 04, 2021
Dr Nasrien Ibrahim discusses the many factors that need to be considered when discussing medical adherence in both HFrEF and HFpEF, as well as improvements needed to help these patients.
EMPEROR-Preserved Trial and Medical Optimization When Treating HFpEF
November 04, 2021
Dr Javed Butler explains the data results from the EMPEROR-Preserved trial and speaks on ways to optimize treatment for patients with HFpEF.